Skip to main content

Table 2 Univariate analysis of factors affecting biochemical free survival

From: Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation

Factor HR (95% CI) p-value
GS 1.299 (1.009–1.672) 0.042
 < 8 1 (reference)
 8–10 2.007 (1.129–3.569) 0.018
bPSA (ng/ml) 1.009 (1.001–1.017) 0.024
 ≤ 20 ng/ml 1 (reference)
 > 20 ng/ml 1.767 (0.970–3.218) 0.063
T-stage 2.226 (1.410–3.515) 0.001
 T1-T2 1 (reference)
 T3-T4 3.079 (1.691–5.608) <0.001
nPSA (ng/ml) 2.667 (1.79–3.973) <0.001
 < 0.06 1 (reference)
 ≥ 0.06 3.887 (1.988–7.599) <0.001
RT dose (Gy) 0.837 (0.703–0.996) 0.045
PSA pre-RT (ng/ml) 1.056 (1.0–1.114) 0.048
ADT duration (months) 0.996 (0.970–1.023) 0.784
Age (years) 0.968 (0.926–1.012) 0.148
Time to Nadir (months) 0.999 (0.969–1.031) 0.965